Caribou Biosciences Inc. (NASDAQ: CRBU) reported extended follow-up data for its CB-011 therapy in treating relapsed or refractory multiple myeloma patients. The data was presented at the 2026 European Hematology Association Annual Meeting.

In the dose escalation portion of the CaMMouflage phase 1 trial, 12 BCMA-naïve patients received the recommended dose of 450 million CB-011 CAR-T cells. With a median follow-up of 17.7 months, the treatment showed a 92% overall response rate and an 83% complete response rate. Additionally, 91% of evaluable patients achieved minimal residual disease negativity, and 50% of patients maintained complete response at 15 months.

The company also reported on a 71-year-old patient who had received eight prior therapies, including an approved autologous CAR-T cell therapy. This patient achieved a complete response at day 28 after receiving CB-011, which remained ongoing as of the May 26, 2026 data cutoff.

Safety data showed no cases of graft-versus-host disease across all 48 patients treated. In the recommended dose cohort, one patient experienced grade 3 or higher cytokine release syndrome, and no patients had grade 3 or higher neurotoxicity syndrome.

CB-011 is an allogeneic anti-BCMA CAR-T cell therapy designed with immune cloaking technology. The therapy has received FDA RMAT, Fast Track, and Orphan Drug designations for relapsed or refractory multiple myeloma.

Caribou expects to report initial dose expansion data from both BCMA-naïve and BCMA-exposed patients in the second half of 2026.